Results 71 to 80 of about 181,578 (308)

Stem-cell-based gene therapy for HIV infection. [PDF]

open access: yes, 2013
Despite the enormous success of combined anti-retroviral therapy, HIV infection is still a lifelong disease and continues to spread rapidly worldwide. There is a pressing need to develop a treatment that will cure HIV infection.
Kitchen, Scott, Zhen, Anjie
core   +2 more sources

Identification of functional murine mitochondrial formyl peptides and their effects on myeloid‐derived suppressor cell generation

open access: yesFEBS Open Bio, EarlyView.
We first identified functional murine mitochondrial N‐formyl peptides (MT‐FPs) and investigated their effects on the in vitro myeloid‐derived suppressor cell (MDSC) generation from bone marrow cells. We demonstrated that MT‐FPs acted directly on bone marrow cells to promote MDSC generation and modulated the polymorphonuclear (PMN)‐MDSC/monocyte (M ...
Miyako Ozawa   +2 more
wiley   +1 more source

T cell receptor-engineered T cells for leukemia immunotherapy

open access: yesCancer Cell International, 2019
At present, refractory and relapse are major issues for leukemia therapy and a major cause of allogeneic hematopoietic stem cell transplant failure. Over the last decade, many studies have demonstrated that adoptive cancer antigen-specific T cell therapy
Yikai Zhang, Yangqiu Li
doaj   +1 more source

Generation and in vivo characterization of a chimeric αvβ5-targeting antibody 14C5 and its derivatives [PDF]

open access: yes, 2013
Background: Previous studies showed that radiolabeled murine monoclonal antibody (mAb) 14C5 and its Fab and F(ab')2 fragments, targeting αvβ5 integrin, have promising properties for diagnostic and therapeutic applications in cancer.
De Vos, Filip   +5 more
core   +2 more sources

Development of human monoclonal antibodies against TARM1 by yeast display

open access: yesFEBS Open Bio, EarlyView.
Human monoclonal antibodies against TARM1 are generated by yeast display‐guided selection. These antibodies bind to soluble and cell‐surface forms of TARM1. Also, these antibodies exhibit agonistic activity in the NFAT‐GFP reporter assay, indicating that TARM1 signaling can be functionally modulated by antibodies and suggesting TARM1 as a potential ...
Rikio Yabe   +5 more
wiley   +1 more source

Therapeutic applications of engineered chimeric antigen receptors-T cell for cancer therapy

open access: yesBeni-Suef University Journal of Basic and Applied Sciences, 2022
Background Findings of new targeted treatments with adequate safety evaluations are essential for better cancer cures and mortality rates. Immunotherapy holds promise for patients with relapsed disease, with the ability to elicit long-term remissions ...
Amina Hussain
doaj   +1 more source

Chimeric Antigen Receptors Expand the Repertoire of Antigenic Macromolecules for Cellular Immunity

open access: yesCells, 2021
T-cell therapies have made significant improvements in cancer treatment over the last decade. One cellular therapy utilizing T-cells involves the use of a chimeric MHC-independent antigen-recognition receptor, typically referred to as a chimeric antigen ...
John T. Keane, Avery D. Posey
doaj   +1 more source

Rescue of a genotype 4 human hepatitis E virus from cloned cDNA and characterization of intergenotypic chimeric viruses in cultured human liver cells and in pigs [PDF]

open access: yes, 2012
Hepatitis E virus (HEV) is an important but extremely understudied human pathogen. Genotypes 1 and 2 are restricted to humans, whereas genotypes 3 and 4 are zoonotic, infecting both humans and pigs.
Alicia R. Feagins   +15 more
core   +1 more source

Anti‐CD19 CAR T Cells in Autoimmune Encephalitis: Inflammation Controlled, Neurodegeneration Unchecked?

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Just recently, successful chimeric antigen receptor (CAR) T cell therapy was reported in the first patient with refractory, anti‐diacylglycerol lipase alpha (DAGLA) antibody‐mediated autoimmune encephalitis, achieving partial clinical remission.
Dimitrios Mougiakakos   +9 more
wiley   +1 more source

Classic and Activating Chimeric Antigen Receptors PD-1 as an Element of Multi-Target Approach to the Treatment of Hematological and Solid Neoplasms

open access: yesКлиническая онкогематология, 2023
Aim. To generate anti-PD-L1 CAR-T effectors carrying extracellular domain PD-1 as antigen-recognizing site and to study their cytolytic activity as well as to functionally assess the anti-PD-L1 CAR-T effectors in vitro with a view to apply them in multi ...
Kseniya Aleksandrovna Levchuk   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy